McDermott Will & Schulte advises V-Bio Ventures, as lead investor on €38 million Series C financing of Step Pharma, the global leader in CTPS1 inhibition for targeted cancer treatment.

The round includes participation from existing investors Pontifax, BPIFrance, Kurma Partners, Hadean Ventures, Sunstone Life Science Ventures and Inserm Transfert Initiative.

The financing will enable Step Pharma to continue advancing its ‘pipeline in a product’ strategy for dencatistat, a first-in-class, highly selective, orally bioavailable CTPS1 inhibitor currently in clinical development for the treatment of cancers and blood disorders.
 
The McDermott team comprised:

• Anthony Paronneau, Partner, Lucie Martin, Counsel, and Alice Villagrasa, associate

Leading organizations turn to global law firm McDermott Will & Schulte for a better way to address legal challenges, connect with those at the forefront, and drive stronger outcomes. Working across more than 20 offices globally, our 1,750+ lawyers act on data-driven insights, deep relationships, and unmatched industry experience to deliver on our commitment of Always Better.